[
    [
        {
            "time": "",
            "original_text": "中国银河证券维持天坛生物推荐评级：业绩符合预期，看好发展前景",
            "features": {
                "keywords": [
                    "天坛生物",
                    "推荐评级",
                    "业绩符合预期",
                    "发展前景"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中国银河证券维持天坛生物推荐评级：业绩符合预期，看好发展前景",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "天坛生物(600161)：业绩符合预期 看好发展前景",
            "features": {
                "keywords": [
                    "天坛生物",
                    "业绩符合预期",
                    "发展前景"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天坛生物(600161)：业绩符合预期 看好发展前景",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "“四大白酒天王”操作大分化 布局有何玄机？",
            "features": {
                "keywords": [
                    "白酒",
                    "天王",
                    "操作分化",
                    "布局"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "食品饮料"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "“四大白酒天王”操作大分化 布局有何玄机？",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "国信证券-天坛生物2020年报及2021一季报点评：Q1业绩略超预期，规模化优势有望进一步扩大【公司研究】",
            "features": {
                "keywords": [
                    "天坛生物",
                    "2020年报",
                    "2021一季报",
                    "Q1业绩略超预期",
                    "规模化优势"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国信证券-天坛生物2020年报及2021一季报点评：Q1业绩略超预期，规模化优势有望进一步扩大【公司研究】",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "29股获券商买入评级 奥园美谷目标涨幅达75.74%",
            "features": {
                "keywords": [
                    "券商买入评级",
                    "奥园美谷",
                    "目标涨幅"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "房地产"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "29股获券商买入评级 奥园美谷目标涨幅达75.74%",
                "Correlation": 1,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        }
    ]
]